Opinion
Video
Author(s):
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
OS Disparity, Driver Gene Variations by Race and Ethnicity Seen in CRC
Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials